<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutrients</journal-id><journal-id journal-id-type="iso-abbrev">Nutrients</journal-id><journal-id journal-id-type="pmc-domain-id">1692</journal-id><journal-id journal-id-type="pmc-domain">nutrients</journal-id><journal-id journal-id-type="publisher-id">nutrients</journal-id><journal-title-group><journal-title>Nutrients</journal-title></journal-title-group><issn pub-type="epub">2072-6643</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429915</article-id><article-id pub-id-type="pmcid-ver">PMC12429915.1</article-id><article-id pub-id-type="pmcaid">12429915</article-id><article-id pub-id-type="pmcaiid">12429915</article-id><article-id pub-id-type="doi">10.3390/nu17172881</article-id><article-id pub-id-type="publisher-id">nutrients-17-02881</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Myristic Acid Remodels Sphingolipid Metabolism via Dual Pathways: Canonical d18-Sphingolipid Regulation and Non-Canonical d16-Sphingolipid Synthesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="Y">Yunfei</given-names></name><xref rid="fn1-nutrients-17-02881" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zeng</surname><given-names initials="Q">Qinghe</given-names></name><xref rid="fn1-nutrients-17-02881" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Z">Zhenying</given-names></name><xref rid="fn1-nutrients-17-02881" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Y">Yu</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhan</surname><given-names initials="M">Mengmin</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yanlu</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2716-2627</contrib-id><name name-style="western"><surname>Duan</surname><given-names initials="J">Jingjing</given-names></name><xref rid="c1-nutrients-17-02881" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Snider</surname><given-names initials="AJ">Ashley J.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-nutrients-17-02881">Sphingolipid Metabolism and Aging, Human Aging Research Institute (HARI) and School of Life Science, Nanchang University, and Jiangxi Key Laboratory of Aging and Disease, Nanchang 330031, China<email>whozing@ncu.edu.cn</email> (Z.H.); <email>wangyanlu@ncu.edu.cn</email> (Y.W.)</aff><author-notes><corresp id="c1-nutrients-17-02881"><label>*</label>Correspondence: <email>duan.jingjing@ncu.edu.cn</email></corresp><fn id="fn1-nutrients-17-02881"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">495755</issue-id><elocation-id>2881</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>03</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>04</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nutrients-17-02881.pdf"/><abstract><p><bold>Background</bold>: Myristic acid (MA), a 14-carbon saturated fatty acid, serves as a precursor for the synthesis of non-canonical d16-sphingoid bases via its activated form, C14:0-CoA. However, its broader regulatory role in sphingolipid (SL) metabolism remains poorly defined. <bold>Methods</bold>: Using HepG2 cells treated with 50 &#956;M MA, we found that sphingolipidomic analysis revealed reprogrammed sphingolipid metabolism. <bold>Results</bold>: In the canonical d18-SL pathway, MA directs its activated product C14:0-CoA into ceramide <italic toggle="yes">N</italic>-acyl chains and downstream metabolites&#8212;especially d18:1-C14:0 hexosylceramide. Concurrently, in the non-canonical d16-SL pathway, MA promotes d16-SL synthesis, especially d16:1-ceramides (Cer), d16:1-hexosylceramides (HexCer), and d16:1-C14:0 lactosylceramide. MA treatment further induced a coordinated shift in cellular sphingolipid pools, characterized by a significant increase in total ceramide levels (encompassing both d16- and d18-species) alongside concurrent reductions in total sphingomyelin (SM) contents. At the gene transcriptional level, MA significantly suppressed <italic toggle="yes">SPTLC2</italic> mRNA expression while markedly upregulating <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> mRNA levels. <bold>Conclusions</bold>: Collectively, these findings position MA as a potent regulator of sphingolipid homeostasis, orchestrating dual pathway modulation: disrupting canonical d18-SL equilibrium through the selective enrichment of <italic toggle="yes">N</italic>-acyl C14:0-containing SLs, and activating non-canonical d16-SL synthesis. This dual pathway regulation reveals that dietary saturated fatty acids exploit sphingolipid subnetworks to regulate lipid metabolism. The interplay between dietary fatty acids and sphingolipid metabolism still requires deeper exploration. Our findings offer preliminary insights into their roles in regulating both normal and disease-associated lipid metabolism, setting the stage for subsequent mechanistic investigations.</p></abstract><kwd-group><kwd>myristic acid</kwd><kwd>sphingolipid metabolism</kwd><kwd>ceramides</kwd><kwd>d16-sphingolipids</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>82171551</award-id><award-id>3247110409</award-id></award-group><award-group><funding-source>Jiangxi Provincial Natural Science Foundation</funding-source><award-id>20242BAB23056</award-id><award-id>20232ACB205002</award-id></award-group><award-group><funding-source>Jiangxi Provincial Natural Science Foundation</funding-source><award-id>20242BAB20273</award-id></award-group><award-group><funding-source>Jiangxi Provincial Graduate Innovation Special Fund</funding-source><award-id>YC2021-B020</award-id></award-group><funding-statement>This work received financial support by funding from the National Natural Science Foundation of China (82171551, 3247110409) and Jiangxi Provincial Natural Science Foundation (20242BAB23056, 20232ACB205002) to Jingjing Duan, Jiangxi Provincial Natural Science Foundation (20242BAB20273) to Zhenying Hu, and the Jiangxi Provincial Graduate Innovation Special Fund (Innovation fund No. YC2021-B020) to Yunfei You.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-nutrients-17-02881"><title>1. Introduction</title><p>Myristic acid (MA), a 14-carbon saturated fatty acid, is predominantly sourced from milk fat, coconut oil, and palm kernel oil, accounts for approximately 0.07&#8211;0.44% (up to 2.0% in some regions) of total dietary energy [<xref rid="B1-nutrients-17-02881" ref-type="bibr">1</xref>,<xref rid="B2-nutrients-17-02881" ref-type="bibr">2</xref>]. Following intestinal absorption, it is catalyzed by acyl-CoA synthetase to form the key metabolic intermediate myristoyl-CoA (C14:0-CoA) [<xref rid="B3-nutrients-17-02881" ref-type="bibr">3</xref>]. This activated MA not only provides energy via <italic toggle="yes">&#946;</italic>-oxidation and modulates plasma, liver, and adipose tissue fatty acid profiles [<xref rid="B3-nutrients-17-02881" ref-type="bibr">3</xref>,<xref rid="B4-nutrients-17-02881" ref-type="bibr">4</xref>], but also serves as a crucial substrate for several important biochemical processes, including protein <italic toggle="yes">N</italic>-myristoylation and the biosynthesis of triacylglycerols, phospholipids, and sphingolipids [<xref rid="B5-nutrients-17-02881" ref-type="bibr">5</xref>,<xref rid="B6-nutrients-17-02881" ref-type="bibr">6</xref>].</p><p>MA may exert dualistic effects on health, simultaneously exhibiting both protective and detrimental impacts depending on physiological context. Moderate amounts of MA not only mitigate age-related intervertebral disk degeneration in naturally aging mice by suppressing endplate chondral remodeling and preventing vertebral osteoporosis (10 and 50 &#956;M MA) [<xref rid="B7-nutrients-17-02881" ref-type="bibr">7</xref>], but also enhance triglyceride and fatty acid deposition in broiler chicken pectoralis muscle to improve muscle quality (0.04% MA in diet) [<xref rid="B8-nutrients-17-02881" ref-type="bibr">8</xref>]. On the other hand, excessive MA disrupts systemic lipid homeostasis by elevating total cholesterol, LDL-C, and HDL-C levels while exacerbating ceramide-dependent lipotoxicity [<xref rid="B9-nutrients-17-02881" ref-type="bibr">9</xref>,<xref rid="B10-nutrients-17-02881" ref-type="bibr">10</xref>], and contributes to pathological tissue remodeling through C14-ceramides (Cer)-mediated myocardial hypertrophy and intestinal stress, concomitantly impairing cell membrane function and signal transduction [<xref rid="B3-nutrients-17-02881" ref-type="bibr">3</xref>,<xref rid="B5-nutrients-17-02881" ref-type="bibr">5</xref>,<xref rid="B11-nutrients-17-02881" ref-type="bibr">11</xref>,<xref rid="B12-nutrients-17-02881" ref-type="bibr">12</xref>,<xref rid="B13-nutrients-17-02881" ref-type="bibr">13</xref>]. These dichotomous effects arise from MA&#8217;s involvement in activating TLR4/NF-&#954;B signaling to promote inflammation [<xref rid="B14-nutrients-17-02881" ref-type="bibr">14</xref>,<xref rid="B15-nutrients-17-02881" ref-type="bibr">15</xref>], while also facilitating oncogenic pathways through protein <italic toggle="yes">N</italic>-myristoylation [<xref rid="B16-nutrients-17-02881" ref-type="bibr">16</xref>]. Notably, it has been found that MA&#8217;s sphingolipid metabolic remodeling, characterized by C14-Cer generation, simultaneously influences cell membrane dynamics and intercellular communication, underscoring its role in sphingolipid (SL) metabolic regulation, which plays a crucial part in cellular function.</p><p>Ceramides sit at the metabolic crossroads of sphingolipid biosynthesis, serving as the central node where three primary synthetic routes converge: <italic toggle="yes">de novo</italic> synthesis from sphingoid bases, hydrolysis of complex sphingolipids including glycosphingolipids (GSLs) and sphingomyelins (SMs), and the salvage pathway that recycles sphingoid base-1-phosphate (S1P) [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. The <italic toggle="yes">de novo</italic> synthesis pathway is initiated by the serine palmitoyltransferase (SPT) [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. The SPT complex is composed of SPTLC1 and SPTLC2 subunits that preferentially utilizes palmitoyl-CoA (C16:0-CoA) and serine as substrates to produce an 18-carbon backbone sphinganine, d18:0 [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. SPT can also utilize alanine in place of serine to generate 18-carbon backbone 1-deoxysphinganine, m18:0 [<xref rid="B18-nutrients-17-02881" ref-type="bibr">18</xref>]. The sphinganine intermediate is subsequently <italic toggle="yes">N</italic>-acylated by ceramide synthases (CERSs) to form dihydroceramides (DHCer), which are then desaturated by desaturase enzyme (DEGS) to yield canonical d18-Cer (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. The C14:0-CoA derived from MA can be utilized by SPTLC1 and SPTLC3 composed SPT complex as a substitute for C16:0-CoA, catalyzing the synthesis of non-canonical d16-sphingoid bases characterized by a 16-carbon sphingosine backbone [<xref rid="B19-nutrients-17-02881" ref-type="bibr">19</xref>]. In this way, MA serves as a key regulatory molecule in maintaining sphingolipid homeostasis.</p><p>While MA has been shown to participate in the synthesis of non-canonical d16-sphingoid bases and d16:1-Cer, its regulatory role in canonical d18-SL metabolism, and whether MA affects the generation of downstream d16:1-complex sphingolipids, remain poorly understood. To address this knowledge gap, we employed HepG2 cells as an in vitro model of hepatic fatty acid metabolism, combined with sphingolipidomic analysis to investigate the effects of MA on both canonical d18-SLs and non-canonical d16-SLs. This approach aims to provide novel insights into the impact of MA on sphingolipid homeostasis.</p></sec><sec id="sec2-nutrients-17-02881"><title>2. Materials and Methods</title><sec id="sec2dot1-nutrients-17-02881"><title>2.1. Reagents</title><p>The myristic acid (MA, Sigma, St. Louis, MO, USA, #M3128, purity &#8805; 98%, BHT-free) was sourced in powder form, dissolved in ethanol to reach a 50 mM concentration for stock solutions, stored at &#8722;20 &#176;C, and used within a week. To maintain analytical precision, fresh working solutions were made each day. The internal standard (Sphingolipid Mix II, Avanti Polar Lipids, Alabaster, AL, USA, #LM-6005, containing d17:0, d17:1, d17:0-sphinganine-1-phosphate (Sa1P) or d17:1-sphingosine-1-phosphate (S1P), C12-ceramide (Cer), C12-sphingomyelin (SM), C12-glucosylceramide (GluCer), C12-lactosylceramide (LacCer, D-lactosyl-ceramide) was confirmed to have a purity exceeding 95% and to be within 10% of the designated concentration (25 &#956;M). For lipid extraction and LC-MS/MS analysis, HPLC-grade or higher purity solvents and chemicals were used, comprising methanol (Sigma, USA, #34860), isopropanol (Merck, Darmstadt, Germany, #1.01040), and formic acid (Macklin, Shanghai, China, #809712). Additional reagents from Sigma (USA) were chloroform (#39918; used for phase separation), dichloromethane (#34856; used for lipid layer separation), acetonitrile (#34851; low UV absorbance for MS compatibility), ammonium formate (#70221; 5 mM stock for buffer preparation), and ammonium acetate (#73594; applied for pH stabilization of samples).</p></sec><sec id="sec2dot2-nutrients-17-02881"><title>2.2. Preparation and Treatment of Cell Cultures</title><p>HepG2 cells (Kunming, China, #KCB200507YJ) were routinely maintained in a complete growth medium consisting of the following: Dulbecco&#8217;s modified Eagle medium (DMEM, high glucose) purchased from Biological Industries (Beit HaEmek, Israel, #10-013), fetal bovine serum (FBS, heat-inactivated) supplied by Clarke Bioscience (Shanghai, China, #FB25015) at a final concentration of 10%, and penicillin-streptomycin (PS) from Solarbio (Beijing, China, #P1400) at a 1% working concentration.</p><p>A density of 1.0 &#215; 10<sup>7</sup> HepG2 cells per dish was used to seed 10 cm culture dishes, and they were cultured for 12 h under standard conditions. Unless stated otherwise, cells were then exposed to 50 &#181;M MA for 24 h. Test compounds were prepared from ethanol-based stock solutions, diluted to working concentrations, and precomplexed with 10% bovine serum albumin (BSA, Sigma, USA, #V900933) for 30 min at 55 &#176;C. This mixture was added to complete growth medium, immediately before cell treatment. The molar ratio of MA to BSA was 33.2:1 during the conjugation step. The final BSA concentration in all treatment and control media was 0.005%. The final ethanol concentration was 0.5 &#181;L/mL of medium (0.05% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). Controls were exposed to ethanol (vehicle) alone at the same volume, conjugated with BSA using the same protocol. To exclude potential confounding effects of cytotoxicity, cell viability was assessed using an MTS assay (Promega, Madison, WI, USA, #G3580) after all treatments.</p></sec><sec id="sec2dot3-nutrients-17-02881"><title>2.3. Lipid Extraction</title><p>Cells were collected at 80&#8211;90% confluence and then mechanically detached using a cell scraper, following two rinses with ice-cold phosphate-buffered saline (PBS). Cell pellets were gently resuspended in 150 &#956;L of Milli-Q water to obtain a homogeneous suspension. Lipid extraction was conducted utilizing a modified version of the methodology out-lined in our prior research [<xref rid="B20-nutrients-17-02881" ref-type="bibr">20</xref>,<xref rid="B21-nutrients-17-02881" ref-type="bibr">21</xref>]. Single-phase and two-phase extractions were performed on the target sphingolipids. After adding the extraction solvent, 10 &#956;L of internal standard was introduced as the internal control. The lipid extraction protocol involved overnight static incubation at 48 &#176;C, followed by saponification, neutralization, sequential solvent extraction (primary and twice re-extraction). Detailed procedures are provided in <xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S1</xref>. The combined extracted phases were dried under a nitrogen stream. Prior to ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), the samples were reconstituted in 250 &#956;L extract liquid, centrifuged at 12,000 rpm for 10 min, and the resulting supernatants were collected for sphingolipid analysis. Following centrifugation, each supernatant was applied to sphingolipid analysis. Data on the recovery of samples calculated against the internal standard and intra/inter-day coefficients of variation (intra/inter-day CV) are provided in <xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S2</xref>; based on the corrected values, the extraction efficiency of this method is over 80%.</p></sec><sec id="sec2dot4-nutrients-17-02881"><title>2.4. LC-MS/MS Profiling</title><p>Sphingolipid analysis was conducted with an ultra-high performance liquid chromatography (UPLC, Shimadzu, Kyoto, Japan) system coupled to a Triple Quad&#8482; 5500+ QTRAP&#8482; MS (AB Sciex, Concord, ON, Canada), which included an LC-30AD binary pump, DGU-20A5 degasser, SIL-30AC autosampler, CTO-20AC column oven, and CBM-20A system controller [<xref rid="B20-nutrients-17-02881" ref-type="bibr">20</xref>,<xref rid="B22-nutrients-17-02881" ref-type="bibr">22</xref>]. The mass spectrometer (MS) was operated in electrospray ionization (ESI+) mode for multiple reaction monitoring (MRM) (<xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S3</xref>). The ion source parameters were configured as: ESI voltage, 4.5 kV; source temperature, 40 &#176;C; ion source gas 1 (nebulizer), 60 psi; and curtain gas, 40 psi. Dwell duration was adjusted to 50 ms, and then to 5 ms for inter-channel delay. Analyst 1.7.3 software (Applied Biosystems, Waltham, MA, USA) was used for instrument control and data acquisition. The Pierce BCA protein assay Kit (Thermo Scientific, Waltham, MA, USA, #23225) was used to standardize the quantification of sphingolipids against the concentration of proteins. UPLC conditions for sphingolipid analysis are provided in <xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S4</xref>.</p><p>Quantification was performed using SCIX OS software (Version 3.0.0.3339, Applied Biosystems). Concentration of each target sphingolipid was calculated using the formula: picomoles of analyte = correction factor &#215; (analyte peak area/internal standard peak area) &#215; picomoles of internal standard added. Sphingolipids with <italic toggle="yes">N</italic>-acyl chain lengths (C12, C16:0, C18:1, C20:0, C24:0, and C24:1) were quantified by comparison with authentic standards and their corresponding internal standards: C12 Cer, SM, GluCer and LacCer. Correction factors for other <italic toggle="yes">N</italic>-acyl chain length species (C18:0, C20:1, C22:0, and C26:0) were derived from standards based on the observed relationship between chain length and peak area [<xref rid="B23-nutrients-17-02881" ref-type="bibr">23</xref>]. The internal standard was the C12-Cer, which was used to quantify Cer. Similarly, internal standards were applied to SMs, hexosylceramides (HexCer, which represent the total of isomers glucosyl-and galactosyl-ceramides) and LacCer using the following respective standards: C12-GluCer (for HexCer and SMs), and C12-LacCer (for LacCer). Sphingoid bases and sphingoid base-1-phosphate were quantified by utilizing d17:0, d17:1, d17:0-Sa1P or d17:1-S1P as internal standards. The developed LC-MS/MS method was validated for linearity, limit of detection (LOD), and lower limit of quantification (LLOQ); inter- and intra-day precision (%CV) were below 15% (<xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S2</xref>), and all analytes demonstrated good stability under all tested conditions.</p></sec><sec id="sec2dot5-nutrients-17-02881"><title>2.5. Real-Time PCR with Quantitative Analysis</title><p>Total RNA from MA-treated and untreated cells was extracted using RNAiso Plus from TaKaRa (Kusatsu, Japan, #9108), reverse-transcribed with the PrimeScript RT Kit (#RR047A) from the same manufacturer, and analyzed by quantitative real-time PCR (qPCR) using Mei5 Biotechnology&#8217;s 2&#215; M5 HiPer SuperMix (Beijing, China, #MF013-01) with primers from <xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Table S5</xref>. The amplification efficiency of all primers was maintained between 90% and 110%. Relative gene expression was determined by the 2<sup>&#8722;&#916;&#916;Ct</sup> method with <italic toggle="yes">GAPDH</italic> as the control.</p></sec><sec id="sec2dot6-nutrients-17-02881"><title>2.6. Statistical Analysis</title><p>Data are presented as the mean &#177; standard deviation (mean &#177; SD). An un-paired two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test was used to analyze the differences between the MA-treated and untreated groups, with homogeneity of variances confirmed by <italic toggle="yes">F</italic>-test and Welch&#8217;s correction applied for unequal variances; the thresholds for statistical significance were * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001. GraphPad Prism 10.0 from La Jolla (CA, USA) and the R pheatmap package were employed to generate figures. Further details about the analysis parameters and calculated content of each sphingolipid, the <italic toggle="yes">p</italic> values, Cohen&#8217;s d, and confidence intervals (CIs) can be requested from the authors.</p></sec></sec><sec sec-type="results" id="sec3-nutrients-17-02881"><title>3. Results</title><sec id="sec3dot1-nutrients-17-02881"><title>3.1. Myristic Acid Reprograms Canonical d18-Sphingolipid Metabolism</title><p>Myristic acid (MA) is primarily activated to C14:0-CoA by acyl-CoA synthetase (ACS) and then metabolized via <italic toggle="yes">&#946;</italic>-oxidation for energy production or esterified into triglycerides/phospholipids (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>A) [<xref rid="B3-nutrients-17-02881" ref-type="bibr">3</xref>,<xref rid="B24-nutrients-17-02881" ref-type="bibr">24</xref>]. A portion of C14:0-CoA undergoes elongation to C16:0 by elongases of very long chain fatty acids (ELOVL) [<xref rid="B25-nutrients-17-02881" ref-type="bibr">25</xref>], while the remainder directly incorporates into ceramides (Cer) or regulates <italic toggle="yes">de novo</italic> sphingolipid synthesis for canonical d18-sphingolipid productions (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>A). To elucidate the impact of MA on canonical d18-sphingolipid profiles, we performed targeted quantification analysis of canonical sphingoid bases including d18:0 and d18:1, Cer including d18:0-dihydroceramides (DHCer) and d18:1-Cer, phosphorylated sphingoid bases d18:0-sphinganine-1-phosphate (Sa1P) and d18:1-sphingosine-1-phosphate (S1P), and glycosphingolipids comprising dihydrohexosylceramides (DHHexCer), hexosylceramides (HexCer), dihydrolactosylceramides (DHLacCer), and lactosylceramides (LacCer).</p><p>We applied a 50 &#956;M treatment concentration of MA for subsequent experiments [<xref rid="B26-nutrients-17-02881" ref-type="bibr">26</xref>], which was verified to exert no cytotoxic effects on cell viability (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S1</xref>). Quantitative analysis of d18-sphingolipids in MA-treated HepG2 cells revealed a complex remodeling of sphingolipid metabolism. While sphinganine d18:0, the product of ketosphinganine reductase (KDSR), exhibited a non-significant decreasing trend (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>B), sphingosine d18:1 was significantly reduced (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>C), indicating diminished <italic toggle="yes">de novo</italic> synthesis of canonical sphingolipids. The m18:0 and m18:1 sphingoid bases, generated through serine palmitoyltransferase (SPT)-catalyzed incorporation of alanine instead of serine as the substrate, were also significantly reduced (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S2A,B</xref>), whereas the level of m18:1-C18:0 ceramide was significantly increased (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S2L</xref>), with m18-Cer remaining unchanged (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S2G,H</xref>). In contrast, d18:0-DHCer remained unchanged (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>D), but d18:1-Cer levels, which are primarily synthesized by ceramide synthases (CERSs), increased markedly (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>E). This was accompanied by a significant reduction in d18:0-Sa1P (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>F) and unchanged d18:1-S1P level (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>G).</p><p>In glycosphingolipid synthesis, total d18:0-DHHexCer, the products of UDP-glucose ceramide glucosyltransferase (UGCG), was markedly decreased (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>H), whereas d18:0-DHLacCer remained unaffected (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>I). The levels of d18:1-HexCer, a substrate for glucosylceramidase (GBA), were stable (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>J), but d18:1-LacCer, synthesis of which were catalyzed by lactosylceramide synthase (GLT), were significantly reduced (<xref rid="nutrients-17-02881-f001" ref-type="fig">Figure 1</xref>K). Collectively, these findings demonstrate that MA reprograms d18-sphingolipid metabolism and preferentially drives d18:1-Cer synthesis while simultaneously inhibiting its conversion to GSLs.</p></sec><sec id="sec3dot2-nutrients-17-02881"><title>3.2. Myristic Acid Suppresses SPTLC2 mRNA Expression and Directs C14:0-CoA into d18:1-Cer/HexCer</title><p>Given the observed alterations in sphingolipid composition, characterized by significant suppression of d18:1 and GSLs including d18:0-DHHexCer and d18:1-LacCer alongside marked elevation of d18:1-Cer, we next examined the mRNA expression levels of key synthetic enzymes involved in their metabolism. Quantitative PCR analysis revealed a downregulation of <italic toggle="yes">SPTLC2</italic> mRNA level among SPT, while with no significant changes in <italic toggle="yes">SPTLC1</italic> or <italic toggle="yes">SPTLC3</italic> mRNA expression (<xref rid="nutrients-17-02881-f002" ref-type="fig">Figure 2</xref>A), suggesting that MA treatment reduced d18-sphingoid bases potentially involving transcriptional modulation of <italic toggle="yes">SPTLC2</italic>, whereas the elevated d16-sphingoid bases may not be directly linked to changes in <italic toggle="yes">SPTLC3</italic> transcription. Notably, no statistically significant differences were detected in the mRNA expression of <italic toggle="yes">DEGS1-2</italic>, <italic toggle="yes">CERS1-6</italic> or <italic toggle="yes">ELOVL1-7</italic> (<xref rid="nutrients-17-02881-f002" ref-type="fig">Figure 2</xref>B,C), indicating that the increased d18:1-Cer levels are unlikely driven by transcriptional upregulation of ceramide synthases or <italic toggle="yes">ELOVLs</italic>. It is also noteworthy that d18:0-Sa1P was significantly reduced, whereas the mRNA expression levels of sphingosine kinases (<italic toggle="yes">SPHK1-2</italic>), S1P phosphatase (<italic toggle="yes">SGPP1</italic>), and S1P lyase (<italic toggle="yes">SGPL1</italic>) remained unchanged (<xref rid="nutrients-17-02881-f002" ref-type="fig">Figure 2</xref>D).</p><p>To further elucidate the compositional changes in canonical d18-sphingolipids, we analyzed the <italic toggle="yes">N</italic>-acyl side chain profiles, which revealed distinct remodeling patterns. In d18:0-DHCer, the <italic toggle="yes">N</italic>-acyl C14:0 showed the most significant increase while C20:0 exhibited a tendency toward downregulation (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>A). The elevation of total d18:1-Cer level was driven not only by the <italic toggle="yes">N</italic>-acyl C14:0 but also by significant increases in C16:0, C18:0, C22:0 and C24:0 side chains (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>B), confirming that MA-derived C14:0-CoA is incorporated into d18-Cer, with potential contributions from elongation of the C14:0 moiety to longer <italic toggle="yes">N</italic>-acyl chains. While d18:0-DHHexCer exhibited significant downregulation of C16:0 and C20:0 side chains (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>C), d18:1-HexCer showed a marked increase in the <italic toggle="yes">N</italic>-acyl C14:0 content accompanied by a clear trend toward elevated levels of C16:0, C18:0, C20:0, and C22:0 (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>D), alongside decreases in C24:0 and C24:1. These changes collectively confirm that MA-derived C14:0-CoA is actively incorporated into d18:1-HexCer, with potential contributions from <italic toggle="yes">N</italic>-acyl C14:0 elongation to longer-chain variants.</p><p>For downstream metabolites, d18:0-DHLacCer displayed no significant alterations in <italic toggle="yes">N</italic>-acyl chain composition (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>E), whereas total d18:1-LacCer levels exhibited a marked decrease, particularly in C16:0, C20:0, C22:0, C24:0, and C24:1 (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>F), with <italic toggle="yes">N</italic>-acyl C14:0-containing d18-LacCer remaining unchanged (<xref rid="nutrients-17-02881-f003" ref-type="fig">Figure 3</xref>E,F). This selective exclusion of <italic toggle="yes">N</italic>-acyl C14:0 from d18-LacCer suggests that MA-derived C14:0-CoA was not efficiently channeled into lactosylceramide synthesis. These findings demonstrate that MA exerts subtype-specific effects on d18-sphingolipid metabolism, preferentially incorporating <italic toggle="yes">N</italic>-acyl C14:0 into d18:1-Cer and d18:1-HexCer, while blocking its further conversion to d18:1-LacCer.</p></sec><sec id="sec3dot3-nutrients-17-02881"><title>3.3. Myristic Acid Drives the Non-Canonical d16-Sphingolipid Biosynthesis</title><p>MA-derived C14:0-CoA serves as a substrate for SPTLC3, the catalytic subunit of the SPT complex, driving the synthesis of d16-sphingoid bases [<xref rid="B19-nutrients-17-02881" ref-type="bibr">19</xref>]. To characterize the resulting d16-sphingolipid species, we performed targeted quantitative sphingolipidomics (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>A). MA treatment significantly elevated d16-sphingoid bases d16:0 (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>B) and d16:1 (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>C). Notably, d16:0 exhibited a greater fold-change than d16:1, indicating the robust activation of <italic toggle="yes">de novo</italic> sphingolipid synthesis despite unchanged <italic toggle="yes">SPTLC3</italic> mRNA levels.</p><p>The elevated d16-sphingoid bases were efficiently channeled into ceramide synthesis, as evidenced by increased d16:0-DHCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>D) and d16:1-Cer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>E). Alternatively, sphingoid bases could be phosphorylated by sphingosine kinases (SPHKs) [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. While d16:0-Sa1P levels were not affected (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>F), d16:1-S1P showed a significant increase (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>G). In glycosphingolipid biosynthesis, ceramides serve as substrates for sequential glycosylation to form HexCer and LacCer [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. Analysis of d16-glycosphingolipids revealed unchanged d16:0-DHHexCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>H) and d16:0-DHLacCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>I), whereas d16:1-HexCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>J) and d16:1-LacCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>K) were significantly upregulated. Collectively, these results demonstrate that MA elevates free d16-sphingoid bases, d16:1-S1P, Cer and GSLs, while the biosynthetic pathways for non-canonical d16-sphingolipids remain functionally intact. The preferential elevation of d16:1-species suggests MA may preferentially channel d16:0-sphingoid base toward specific downstream products rather than uniformly activating the entire pathway.</p><p>To assess compositional changes in DHCer, Cer, HexCer, and LacCer across <italic toggle="yes">N</italic>-acyl chain lengths, we quantified d16-sphingolipid species using mass spectrometry and visualized alterations through fold-change calculations. Quantitative analysis of d16-sphingolipids across acyl chain lengths revealed that MA treatment consistently increased d16:0-DHCer levels (except C18:0), with pronounced elevation at <italic toggle="yes">N</italic>-acyl C14:0 and C16:0 (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>L). It also enhanced d16:1-Cer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>M) and d16:1-HexCer (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>N) across <italic toggle="yes">N</italic>-acyl C14~C24 chains. Conversely, d16:1-LacCer increased only at <italic toggle="yes">N</italic>-acyl C14:0, C20:0, and C22:0, with no significant differences observed at other chain lengths (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>O). Notably, among d16:0- and d16:1-(DH)Cer, (DH)HexCer, and (DH)LacCer, the molecular subtypes acylated with C14:0 all showed the most significant elevation (<xref rid="nutrients-17-02881-f004" ref-type="fig">Figure 4</xref>L&#8211;O and <xref rid="app1-nutrients-17-02881" ref-type="app">Figure S3</xref>). These findings demonstrate MA-derived C14:0-CoA is specifically incorporated into Cer and efficiently metabolized to downstream HexCer and LacCer. In summary, MA-derived C14:0-CoA integrates into d16-sphingolipids, driving efficient metabolism through Cer to S1P and GSL pathways, with <italic toggle="yes">N</italic>-acyl C14:0-acylated species exhibiting the most pronounced increases at all metabolic nodes. These results indicate that MA specifically activates the d16-sphingolipid pathway.</p><p>In addition, among non-canonical sphingolipids, the SPTLC3 can also utilize alternative fatty acids to synthesize d19- and d20-series sphingolipids [<xref rid="B26-nutrients-17-02881" ref-type="bibr">26</xref>,<xref rid="B27-nutrients-17-02881" ref-type="bibr">27</xref>]. Our analysis revealed that while d19:1-sphingoid base level was significantly reduced, other d19- and d20-series free bases and corresponding ceramides remained unchanged (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S2C&#8211;N</xref>).</p></sec><sec id="sec3dot4-nutrients-17-02881"><title>3.4. Myristic Acid Increases Total Cer but Inhibits Total Glycosphingolipids and Sphingomyelins</title><p>Sphingolipid function is determined by both their molecular composition and quantitative abundance. Building on our analysis of individual d18- and d16-sphingolipid species, we further quantified the total pool of these lipids to evaluate their comprehensive metabolic impact. Metabolite profiling revealed that while total d18- and d16-DHCer levels remained unchanged (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>A), total ceramide contents were significantly elevated (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>B). Regarding GSLs, DHHexCer levels decreased markedly (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>C), whereas downstream HexCer remained stable (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>D). Similarly, DHLacCer showed no change (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>E), but LacCer contents were significantly reduced (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>F). In addition to GSLs, MA treatment significantly reduced total sphingomyelin (SM) contents (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>G). However, this overall decrease exhibited pronounced molecular subtype specificity: while most SM subtypes&#8212;including d32:0, d32:1, d34:0, d34:1, d34:2, d36:0, d36:2, d40:0, d40:1, d42:2, d44:1, and d44:2&#8212;were markedly downregulated (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>I), specific subtypes (d30:0-SM, d30:1-SM, d32:2-SM, and d44:0-SM) showed significant increases. Notably, the proportion of d30-SM within total SM rose from 3.83 to 4.05% to 5.40&#8211;5.58% post-treatment. The d30:0-SM and d30:1-SM likely correspond to d16:0-C14:0 and d16:1-C14:0 sphingomyelins, respectively. This dichotomy indicates that, aside from C14:0-containing d16-Cer serving as a precursor for specific elevated SM species, the majority of SM subtypes were reduced by MA treatment.</p><p>SM is synthesized via the choline headgroup transfer reaction catalyzed by sphingomyelin synthase, where ceramide is transported to the Golgi apparatus by CERT, and is primarily degraded by sphingomyelinases SMPD1-3 [<xref rid="B17-nutrients-17-02881" ref-type="bibr">17</xref>]. To better understand the cause of the substantial decrease in total SM contents, we analyzed the expression levels of key genes regulating its synthesis (<italic toggle="yes">CERT</italic>, <italic toggle="yes">SGMS1-2</italic>) and degradation (<italic toggle="yes">SMPD1-3</italic>). The expression of SM phosphodiesterase genes <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> was significantly upregulated (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>H), suggesting that MA may promote SM degradation by enhancing the expression of these genes. While the mRNA expression of <italic toggle="yes">CERT</italic>, which encodes the ceramide transport protein, and SM synthase genes <italic toggle="yes">SGMS1</italic>-<italic toggle="yes">2</italic> was unaffected (<xref rid="nutrients-17-02881-f005" ref-type="fig">Figure 5</xref>H).</p></sec></sec><sec sec-type="discussion" id="sec4-nutrients-17-02881"><title>4. Discussion</title><p>Our current study demonstrates that myristic acid (MA) exerts complex and selective effects on sphingolipid metabolism via multiple pathways: regulation of canonical d18-sphingolipids and stimulation of non-canonical d16-sphingolipid synthesis. Through its incorporation as C14:0-CoA, MA preferentially generates d18:1-ceramides (Cer), but suppresses d18-sphingolipid synthesis by downregulating <italic toggle="yes">SPTLC2</italic> mRNA expression, reducing free sphingoid bases. Simultaneously, MA drives non-canonical d16-sphingolipid production by enabling SPTLC3-dependent synthesis of d16-sphingoid bases, leading to elevated d16-Cer and d16:1-glycosphingolipids (GSLs) such as hexosylceramides (HexCer) and lactosylceramides (LacCer). Additionally, MA enhances sphingomyelin (SM) degradation, potentially via mechanisms involving the upregulation of <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> mRNA, selectively depletes major SM subtypes, and diminishes d18-GSLs including d18:0-dihydrohexosylceramides (DHHexCer) and d18:1-LacCer. Notably, the marked reduction in total sphingomyelin (SM) levels coupled with ceramide accumulation, alongside significant upregulation of <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> mRNA expression, suggests that MA-induced ceramide accumulation may arise from enhanced SM hydrolysis (i.e., SM&#10230;Cer flux). However, it is important to clarify that increased mRNA expression of <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> does not necessarily correlate with elevated enzyme protein levels or enhanced sphingomyelinase (SMase) activities. Future studies should investigate SMase regulation&#8212;for example, by applying specific inhibitors&#8212;to validate this mechanistic hypothesis. Furthermore, CERT (ceramide transporter) is a critical mediator of ceramide trafficking from the endoplasmic reticulum to the Golgi apparatus, where ceramide is converted to SM, thereby involving in the Cer&#10230;SM flux. Although MA treatment did not modulate <italic toggle="yes">CERT</italic> mRNA expression, the pronounced alteration in the Cer/SM balance warrants deeper investigation into CERT and sphingomyelin synthase&#8217;s regulatory role in this context. It should also be emphasized that this study was performed using a single concentration (50 &#956;M MA) in HepG2 cells, without evaluating dose&#8211;response relationships or temporal dynamics. Future research should systematically explore these parameters to provide a more comprehensive mechanistic understanding. Collectively, these coordinated changes establish a distinctive metabolic signature characterized by elevated total Cer, reduced complex sphingolipids (DHHexCer, LacCer, SM), and demonstrate MA&#8217;s ability to differentially modulate lipid flux at multiple nodes, with potential implications for cellular homeostasis and signaling.</p><p>As key precursors for sphingolipid synthesis, the dietary fatty acids participate in the metabolic balance of sphingolipids, and this balance in turn affects physiological functions such as cellular signal transduction [<xref rid="B28-nutrients-17-02881" ref-type="bibr">28</xref>,<xref rid="B29-nutrients-17-02881" ref-type="bibr">29</xref>]. For canonical d18-sphingolipids, MA provides substrates for ceramide synthesis by increasing intracellular C14:0-CoA concentrations, leading to increases in d18:1-Cer (C14~C24). The SPTLC1/SPTLC2 complex catalyzes the <italic toggle="yes">de novo</italic> synthesis of canonical d18-sphingolipids (e.g., d18:0) from serine and palmitoyl-CoA, whereas the SPTLC1/SPTLC3 complex is responsible for producing canonical d16-sphingoid bases (e.g., d16:0) using myristoyl-CoA [<xref rid="B26-nutrients-17-02881" ref-type="bibr">26</xref>]. Notably, the significant reduction in <italic toggle="yes">SPTLC2</italic> mRNA expression, accompanied by a partial decline in <italic toggle="yes">SPTLC1</italic> mRNA level, along with decreased levels of d18:0 and d18:1, collectively indicates impaired <italic toggle="yes">de novo</italic> biosynthesis of d18-sphingolipids. This transcriptional disruption is more likely attributed to feedback inhibition triggered by the accumulation of total ceramides (Cer) [<xref rid="B30-nutrients-17-02881" ref-type="bibr">30</xref>], as the SPTLC3 mRNA level showed no significant change&#8212;suggesting that direct effects of MA treatment are less probable, and the regulation may be predominantly mediated by total Cer-induced negative feedback. Nevertheless, MA treatment reshapes the homeostatic balance between d18- and d16- sphingolipids, along with altering the overall sphingolipid profile. Given that our current data on serine palmitoyltransferase (SPT) subunits are limited to the mRNA level, highlighting a critical gap, future studies should employ Western blotting and SPT activity assays to determine whether MA regulates the protein level and function of SPT through translational or post-translational mechanisms, and <sup>13</sup>C-labeled MA tracing experiments would enable the precise evaluation of MA&#8217;s metabolic flux into distinct d18- versus d16-sphingolipid pools, as well as its distribution into other lipid classes (e.g., triglycerides, phospholipids). Additional investigations such as co-treatment with palmitate are needed to elucidate how MA modulates the balance of sphingoid bases (e.g., d18, d16) and derived sphingolipids.</p><p>Current knowledge regarding the functional consequences of dietary MA uptake and the physiological significance of d16-sphingolipids remains limited. It is demonstrated that MA-derived C14:0-CoA is utilized by SPTLC3 to generate non-canonical d16-sphingoid bases and Cer [<xref rid="B19-nutrients-17-02881" ref-type="bibr">19</xref>]. Lone et al. demonstrated that only <italic toggle="yes">SPTLC3</italic>-overexpressed cells were capable of synthesizing canonical d16-sphingolipids upon MA supplementation in HEK293 [<xref rid="B26-nutrients-17-02881" ref-type="bibr">26</xref>], and our recent study further confirmed a significant increase in d16:0 in the livers of <italic toggle="yes">Sptlc3</italic>-overexpressed mice (<xref rid="app1-nutrients-17-02881" ref-type="app">Figure S4</xref>). To investigate the function of SPTLC3 in this process, future studies should incorporate <italic toggle="yes">SPTLC3</italic> knockdown models combined with MA treatment to evaluate d16-sphingolipid production. The current study reveals that d16-Cer preferentially form downstream d16:1-GSLs including HexCer and LacCer, as well as SMs, rather than d16:0-types. This emerging class of non-canonical d16-sphingolipids has garnered increasing attention due to their significant elevation in multiple pathologies, including type 2 diabetes, insulin resistance, non-alcoholic fatty liver disease, and cardiovascular disease [<xref rid="B31-nutrients-17-02881" ref-type="bibr">31</xref>,<xref rid="B32-nutrients-17-02881" ref-type="bibr">32</xref>,<xref rid="B33-nutrients-17-02881" ref-type="bibr">33</xref>,<xref rid="B34-nutrients-17-02881" ref-type="bibr">34</xref>,<xref rid="B35-nutrients-17-02881" ref-type="bibr">35</xref>,<xref rid="B36-nutrients-17-02881" ref-type="bibr">36</xref>,<xref rid="B37-nutrients-17-02881" ref-type="bibr">37</xref>]. Notably, Kovilakath et al. recently identified that d16 non-canonical sphingolipids, particularly d16-LacCer, were critical mediators of myocardial injury in ischemic cardiomyopathy, where they disrupt mitochondrial membrane integrity and complex I subunit composition [<xref rid="B36-nutrients-17-02881" ref-type="bibr">36</xref>]. In MA-treated hepatic cells, we observed a significant increase in d16:1-LacCer levels, while strikingly, total LacCer levels (comprising both d18 and d16 species) were reduced. This selective redistribution of LacCer subtypes warrants further investigation into its potential impact on mitochondrial function and diseases. Sustained elevation of d16:1-sphingosine-1-phosphate (S1P) in rat intestinal IEC-6 cells following MA treatment occurred without concomitant changes in d16:0-sphinganine-1-phosphate (Sa1P) levels [<xref rid="B38-nutrients-17-02881" ref-type="bibr">38</xref>], paralleling our hepatic cell findings. Given that d16:1-S1P serves as a critical signaling regulator of cell survival similar to d18-S1P [<xref rid="B39-nutrients-17-02881" ref-type="bibr">39</xref>,<xref rid="B40-nutrients-17-02881" ref-type="bibr">40</xref>], our findings indicate that MA may participate in S1P-GPCR axis-mediated cell fate decisions.</p><p>At the systemic level, MA treatment increased total ceramide levels (d16 + d18) while decreasing complex sphingolipids (GSLs and SMs). Elevation in Cer may contribute to pathological processes including apoptosis, inflammation, stress responses, and metabolic homeostasis disruption [<xref rid="B41-nutrients-17-02881" ref-type="bibr">41</xref>,<xref rid="B42-nutrients-17-02881" ref-type="bibr">42</xref>,<xref rid="B43-nutrients-17-02881" ref-type="bibr">43</xref>,<xref rid="B44-nutrients-17-02881" ref-type="bibr">44</xref>], and diminished GSL biosynthesis restores insulin signaling in adipocytes, enhances adipogenesis, and alleviates skin inflammation [<xref rid="B45-nutrients-17-02881" ref-type="bibr">45</xref>,<xref rid="B46-nutrients-17-02881" ref-type="bibr">46</xref>]. Collectively, our results demonstrate that MA remodels the molecular composition of sphingolipid subtypes. These findings may be particularly relevant for patients with cardiovascular or metabolic disorders requiring specialized dietary interventions. However, further validation through co-treatment with other fatty acids&#8212;especially palmitate&#8212;is warranted to compare the effects of different saturated fatty acids on sphingolipid metabolic flux and to elucidate MA&#8217;s systemic role in sphingolipid metabolism-related health issues.</p></sec><sec sec-type="conclusions" id="sec5-nutrients-17-02881"><title>5. Conclusions</title><p>Our current study demonstrates that myristic acid (MA) exerts a dual regulatory effect on sphingolipid metabolism. One facet of this effect is that, through acyl-CoA pool expansion, MA achieves a nuanced sphingolipid remodeling, characterized by the enhanced synthesis of C14-sphingolipids, preferential enrichment of diverse canonical d18:1-ceramides (Cer), and a concurrent reduction in d18-complex sphingolipids. Another facet is that MA activates the <italic toggle="yes">de novo</italic> synthesis of non-canonical d16-sphingolipids, including d16-sphingoid bases, d16-Cer, d16-hexosylceramides (HexCer), d16-lactosylceramides (LacCer) and some potential d16-sphingomyelins (SMs). Concomitantly, MA treatment was associated with transcriptional regulation in sphingolipid metabolism-related enzymes, featuring decreased <italic toggle="yes">SPTLC2</italic> mRNA levels, and increased <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic> mRNA levels. Our findings offer primary but novel insights into how the uptake of the dietary fatty acid MA regulates sphingolipid metabolism, providing valuable perspectives for understanding and addressing human health issues related to lipid metabolism disorders.</p></sec></body><back><ack><title>Acknowledgments</title><p>We gratefully acknowledge Huaiyi Zhu and Shenlong Mo for their great helps with mass spectrometry data analysis and revisions of the manuscript. We also appreciate Lingfeng Xiong&#8217;s essential contributions to the foundational work enabling this study.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-nutrients-17-02881"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/nu17172881/s1">https://www.mdpi.com/article/10.3390/nu17172881/s1</uri>, Figure S1. Cell viabilities of HepG2 cells treated with various concentration of myristic acid. The viability of HepG2 cells treated with myristic acid (MA) (0-500 &#956;M, 24 h) was evaluated with the MTS assay, normalized to untreated controls. Statistical analysis via a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test indicated no significant differences (all <italic toggle="yes">p</italic> &gt; 0.05, ns) compared to the control. Data are from three independent biological replicates (black dots indicate individual replicates). Figure S2. The effect of MA on non-canonical m18- 1-deoxysphingolipids and d19-, d20- sphingolipids. (A,B) Quantification of 1-deoxysphingoid bases showed reduced levels of (A) m18:0 and (B) m18:1 (units: pmol/mg protein). (C&#8211;F) Analysis of d19- and d20- sphingoid bases demonstrated a decrease in (D) d19:1, whereas (C) d19:0, (E) d20:0, and (F) d20:1 remained unchanged (units: pmol/mg protein). (G&#8211;J) Corresponding ceramide analysis showed that the levels of (G) m18:0-DHCer, (H) m18:1-Cer, (I) d19:1-Cer, and (J) d20:1-Cer were unaffected (units: pmol/mg protein). (K,L) Heatmaps of m18:0-DHCer (K) and m18:1-Cer (L) <italic toggle="yes">N</italic>-acyl chain distributions (C14~C24) as log<sub>2</sub>-fold changes. (M,N) Heatmaps displaying d19:1-Cer (M) and d20:1-Cer (N) chain length modifications (C16~C24) as log<sub>2</sub>-fold changes. For each panel, the maximum positive (red) log<sub>2</sub>FC values and their corresponding fold changes are: 0.3 (~1.2-fold), 0.6 (~1.5-fold), 1 (2.0-fold), 2 (4.0-fold). A log<sub>2</sub>FC value of 0 indicates no change from the mean, with positive and negative values representing upward and downward regulation, respectively. Color scale: all analyses were conducted in MA-treated HepG2 cells. Data are from three independent biological replicates (black dots indicate individual replicates). Significance was assessed by a two-tailed <italic toggle="yes">t</italic>-test (* <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01). Figure S3. The effect of MA on d16:0-dihydrohexosylceramides (DHHexCer), and d16:0-dihydrolactosylceramides (DHLacCer). Heatmaps displaying (A) d16:0-DHHexCer and (B) d16:0-DHLacCer with C16~C24 acyl chain length as log<sub>2</sub>-fold changes. Color scale: all analyses were conducted in MA-treated HepG2 cells. Statistical significance was determined by two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test (n = 3 independent experiments), with * <italic toggle="yes">p</italic> &lt; 0.05, and ** <italic toggle="yes">p</italic> &lt; 0.01. Figure S4. Fold change in sphinganine d16:0 in WT and <italic toggle="yes">Sptlc3</italic><sup>OE</sup> mice at 6 months of age. Liver samples were collected from wild type (WT) and <italic toggle="yes">Sptlc3</italic> over-expressed C57BL/6J mice (SPF-grade, 6-month-old, males), with six mice per group (black dots indicate individual replicates). Statistical significance was determined by two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, with *** <italic toggle="yes">p</italic> &lt; 0.001. Table S1. Single-phase and two-phase lipid extraction protocol for target sphingolipids. Table S2. Validation of optimized LC-MS/MS analysis for each analyte. LOD: limit of detection; LLOQ: limit of quantification; Intra: intra-day; Inter: inter-day. Table S3. Optimized MRM parameters for LC-MS/MS analysis. Table S4. Ultra performance liquid chromatography (UPLC) conditions for sphingolipid analysis. Table S5. Gene-specific primer sequences used for qPCR amplification. The primers were designed based on published gene sequences of <italic toggle="yes">Homo sapiens</italic> (NCBI Reference Sequence Database) using NCBI&#8217;s Primer-BLAST tool (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/tools/primer-blast/">https://www.ncbi.nlm.nih.gov/tools/primer-blast/</uri>, accessed on 3 September 2025). All primers were synthesized by Tsingke (Changsha, China) and validated via PCR a two-step quality control process. PCR amplification followed by Sanger sequencing to confirm target specificity, and gradient PCR optimization to determine optimal annealing temperatures. Primer efficiency was further evaluated using the standard curve method via qRT-PCR.</p><supplementary-material id="nutrients-17-02881-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nutrients-17-02881-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>J.D., Z.H. and Y.W. designed the experiments. Y.Y. and Q.Z. performed the experiments with assistance from Y.C. and M.Z. Z.H. conducted the sphingolipidomic analysis. Y.Y. and Q.Z. processed the data. Y.Y. and J.D. prepared the manuscript. J.D. supervised the project. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/<xref rid="app1-nutrients-17-02881" ref-type="app">Supplementary Materials</xref>, further inquiries can be directed to the corresponding author due to privacy reasons.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors state that they have no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">MA</td><td align="left" valign="middle" rowspan="1" colspan="1">myristic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SL</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingolipid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cer</td><td align="left" valign="middle" rowspan="1" colspan="1">ceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HexCer</td><td align="left" valign="middle" rowspan="1" colspan="1">hexosylceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SM</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingomyelin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C14:0-CoA</td><td align="left" valign="middle" rowspan="1" colspan="1">myristoyl-CoA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GSL</td><td align="left" valign="middle" rowspan="1" colspan="1">glycosphingolipid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">S1P</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingoid base-1-phosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SPT</td><td align="left" valign="middle" rowspan="1" colspan="1">serine palmitoyltransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">C16:0-CoA</td><td align="left" valign="middle" rowspan="1" colspan="1">palmitoyl-CoA</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CERSs</td><td align="left" valign="middle" rowspan="1" colspan="1">ceramide synthases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DHCer</td><td align="left" valign="middle" rowspan="1" colspan="1">dihydroceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DEGS</td><td align="left" valign="middle" rowspan="1" colspan="1">desaturase enzyme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRM</td><td align="left" valign="middle" rowspan="1" colspan="1">multiple reaction monitoring</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GluCer</td><td align="left" valign="middle" rowspan="1" colspan="1">glucosylceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LacCer</td><td align="left" valign="middle" rowspan="1" colspan="1">lactosylceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LOD</td><td align="left" valign="middle" rowspan="1" colspan="1">limit of detection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LLOQ</td><td align="left" valign="middle" rowspan="1" colspan="1">lower limit of quantification</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACS</td><td align="left" valign="middle" rowspan="1" colspan="1">acyl-CoA synthetase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ELOVL</td><td align="left" valign="middle" rowspan="1" colspan="1">elongases of very long chain fatty acids</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DHHexCer</td><td align="left" valign="middle" rowspan="1" colspan="1">dihydrohexosylceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DHLacCer</td><td align="left" valign="middle" rowspan="1" colspan="1">dihydrolactosylceramide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KDSR</td><td align="left" valign="middle" rowspan="1" colspan="1">ketosphinganine reductase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sa1P</td><td align="left" valign="middle" rowspan="1" colspan="1">sphinganine-1-phosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UGCG</td><td align="left" valign="middle" rowspan="1" colspan="1">UDP-glucose ceramide glucosyltransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GBA</td><td align="left" valign="middle" rowspan="1" colspan="1">glucosylceramidase Beta</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GLT</td><td align="left" valign="middle" rowspan="1" colspan="1">galactosyltransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SPHKs</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingosine kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SGPP1</td><td align="left" valign="middle" rowspan="1" colspan="1">S1P phosphatase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SGPL1</td><td align="left" valign="middle" rowspan="1" colspan="1">S1P lyase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CERT</td><td align="left" valign="middle" rowspan="1" colspan="1">ceramide transporter</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SMPD</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingomyelin phosphodiesterase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SGMS</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingomyelin synthase</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-nutrients-17-02881"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arghavani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bilodeau</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Rudkowska</surname><given-names>I.</given-names></name></person-group><article-title>Association Between Circulating Fatty Acids and Blood Pressure: A Review</article-title><source>Curr. Nutr. Rep.</source><year>2025</year><volume>14</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1007/s13668-024-00602-3</pub-id><pub-id pub-id-type="pmid">39775363</pub-id></element-citation></ref><ref id="B2-nutrients-17-02881"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.</given-names></name></person-group><article-title>Dietary intake of saturated fatty acids and the risk of incident diabetes: Associations by isocaloric substitutions in a nationwide Chinese cohort</article-title><source>Eur. J. Nutr.</source><year>2025</year><volume>64</volume><fpage>181</fpage><pub-id pub-id-type="doi">10.1007/s00394-025-03703-z</pub-id><pub-id pub-id-type="pmid">40392293</pub-id></element-citation></ref><ref id="B3-nutrients-17-02881"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giglione</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meinnel</surname><given-names>T.</given-names></name></person-group><article-title>Mapping the myristoylome through a complete understanding of protein myristoylation biochemistry</article-title><source>Prog. Lipid Res.</source><year>2022</year><volume>85</volume><fpage>101139</fpage><pub-id pub-id-type="doi">10.1016/j.plipres.2021.101139</pub-id><pub-id pub-id-type="pmid">34793862</pub-id></element-citation></ref><ref id="B4-nutrients-17-02881"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rioux</surname><given-names>V.</given-names></name><name name-style="western"><surname>Catheline</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bouriel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Legrand</surname><given-names>P.</given-names></name></person-group><article-title>Dietary myristic acid at physiologically relevant levels increases the tissue content of C20:5 n-3 and C20:3 n-6 in the rat</article-title><source>Reprod. Nutr. Dev.</source><year>2005</year><volume>45</volume><fpage>599</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1051/rnd:2005048</pub-id><pub-id pub-id-type="pmid">16188210</pub-id></element-citation></ref><ref id="B5-nutrients-17-02881"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlott</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Holder</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Tate</surname><given-names>E.W.</given-names></name></person-group><article-title>N-Myristoylation as a Drug Target in Malaria: Exploring the Role of N-Myristoyltransferase Substrates in the Inhibitor Mode of Action</article-title><source>ACS Infect. Dis.</source><year>2018</year><volume>4</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00203</pub-id><pub-id pub-id-type="pmid">29363940</pub-id></element-citation></ref><ref id="B6-nutrients-17-02881"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kummrow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>E.A.</given-names></name></person-group><article-title>Myristic acid increases dense lipoprotein secretion by inhibiting apoB degradation and triglyceride recruitment</article-title><source>J. Lipid Res.</source><year>2002</year><volume>43</volume><fpage>2155</fpage><lpage>2163</lpage><pub-id pub-id-type="doi">10.1194/jlr.M200249-JLR200</pub-id><pub-id pub-id-type="pmid">12454278</pub-id></element-citation></ref><ref id="B7-nutrients-17-02881"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Myristic acid beneficially modulates intervertebral disc degeneration by preventing endplate osteochondral remodeling and vertebral osteoporosis in naturally aged mice</article-title><source>Front. Pharmacol.</source><year>2025</year><volume>16</volume><elocation-id>1517221</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2025.1517221</pub-id><pub-id pub-id-type="pmid">40290425</pub-id><pub-id pub-id-type="pmcid">PMC12023261</pub-id></element-citation></ref><ref id="B8-nutrients-17-02881"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J.</given-names></name></person-group><article-title>Effect of myristic acid supplementation on triglyceride synthesis and related genes in the pectoral muscles of broiler chickens</article-title><source>Poult. Sci.</source><year>2024</year><volume>103</volume><fpage>104038</fpage><pub-id pub-id-type="doi">10.1016/j.psj.2024.104038</pub-id><pub-id pub-id-type="pmid">39079330</pub-id><pub-id pub-id-type="pmcid">PMC11340564</pub-id></element-citation></ref><ref id="B9-nutrients-17-02881"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fattore</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bosetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brighenti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Agostoni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fattore</surname><given-names>G.</given-names></name></person-group><article-title>Palm oil and blood lipid-related markers of cardiovascular disease: A systematic review and meta-analysis of dietary intervention trials</article-title><source>Am. J. Clin. Nutr.</source><year>2014</year><volume>99</volume><fpage>1331</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.3945/ajcn.113.081190</pub-id><pub-id pub-id-type="pmid">24717342</pub-id></element-citation></ref><ref id="B10-nutrients-17-02881"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temme</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Mensink</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Hornstra</surname><given-names>G.</given-names></name></person-group><article-title>Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects</article-title><source>J. Lipid Res.</source><year>1997</year><volume>38</volume><fpage>1746</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1016/S0022-2275(20)37149-2</pub-id><pub-id pub-id-type="pmid">9323584</pub-id></element-citation></ref><ref id="B11-nutrients-17-02881"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russo</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Baicu</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Van Laer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kasiganesan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zile</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Cowart</surname><given-names>L.A.</given-names></name></person-group><article-title>Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>3919</fpage><lpage>3930</lpage><pub-id pub-id-type="doi">10.1172/JCI63888</pub-id><pub-id pub-id-type="pmid">23023704</pub-id><pub-id pub-id-type="pmcid">PMC3484448</pub-id></element-citation></ref><ref id="B12-nutrients-17-02881"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Olakkengil</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Ross-Evans</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Cowart</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>A.J.</given-names></name></person-group><article-title>Myristate-induced endoplasmic reticulum stress requires ceramide synthases 5/6 and generation of C14-ceramide in intestinal epithelial cells</article-title><source>FASEB J.</source><year>2018</year><volume>32</volume><fpage>5724</fpage><lpage>5736</lpage><pub-id pub-id-type="doi">10.1096/fj.201800141R</pub-id><pub-id pub-id-type="pmid">29768040</pub-id><pub-id pub-id-type="pmcid">PMC6133702</pub-id></element-citation></ref><ref id="B13-nutrients-17-02881"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-01248-9</pub-id><pub-id pub-id-type="pmid">36617552</pub-id><pub-id pub-id-type="pmcid">PMC9826789</pub-id></element-citation></ref><ref id="B14-nutrients-17-02881"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masetto Antunes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Godoy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Curi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Verg&#237;lio Visentainer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barbosa Bazotte</surname><given-names>R.</given-names></name></person-group><article-title>The Myristic Acid: Docosahexaenoic Acid Ratio Versus the n-6 Polyunsaturated Fatty Acid: N-3 Polyunsaturated Fatty Acid Ratio as Nonalcoholic Fatty Liver Disease Biomarkers</article-title><source>Metab. Syndr. Relat. Disord.</source><year>2022</year><volume>20</volume><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1089/met.2021.0107</pub-id><pub-id pub-id-type="pmid">34813379</pub-id></element-citation></ref><ref id="B15-nutrients-17-02881"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Docosahexaenoic Acid Ameliorates Fructose-Induced Hepatic Steatosis Involving ER Stress Response in Primary Mouse Hepatocytes</article-title><source>Nutrients</source><year>2016</year><volume>8</volume><elocation-id>55</elocation-id><pub-id pub-id-type="doi">10.3390/nu8010055</pub-id><pub-id pub-id-type="pmid">26805874</pub-id><pub-id pub-id-type="pmcid">PMC4728666</pub-id></element-citation></ref><ref id="B16-nutrients-17-02881"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name></person-group><article-title>The role of N-myristoyltransferase 1 in tumour development</article-title><source>Ann. Med.</source><year>2023</year><volume>55</volume><fpage>1422</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1080/07853890.2023.2193425</pub-id><pub-id pub-id-type="pmid">37140999</pub-id><pub-id pub-id-type="pmcid">PMC10161948</pub-id></element-citation></ref><ref id="B17-nutrients-17-02881"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hla</surname><given-names>T.</given-names></name></person-group><article-title>Regulation of cellular and systemic sphingolipid homeostasis</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2024</year><volume>25</volume><fpage>802</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1038/s41580-024-00742-y</pub-id><pub-id pub-id-type="pmid">38890457</pub-id><pub-id pub-id-type="pmcid">PMC12034107</pub-id></element-citation></ref><ref id="B18-nutrients-17-02881"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name></person-group><article-title>1-Deoxysphingolipids and Their Analogs in Foods: The Occurrence and Potential Impact on Human Health</article-title><source>J. Nutr. Sci. Vitaminol.</source><year>2022</year><volume>68</volume><fpage>S146</fpage><lpage>S148</lpage><pub-id pub-id-type="doi">10.3177/jnsv.68.S146</pub-id><pub-id pub-id-type="pmid">36437001</pub-id></element-citation></ref><ref id="B19-nutrients-17-02881"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hornemann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Penno</surname><given-names>A.</given-names></name><name name-style="western"><surname>R&#252;tti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kivrak-Pfiffner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rohrer</surname><given-names>L.</given-names></name><name name-style="western"><surname>von Eckardstein</surname><given-names>A.</given-names></name></person-group><article-title>The SPTLC3 subunit of serine palmitoyltransferase generates short chain sphingoid bases</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>26322</fpage><lpage>26330</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.023192</pub-id><pub-id pub-id-type="pmid">19648650</pub-id><pub-id pub-id-type="pmcid">PMC2785320</pub-id></element-citation></ref><ref id="B20-nutrients-17-02881"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name></person-group><article-title>Accumulation of Fatty Acylated Fusarium Toxin 2-Amino-14, 16-dimethyloctadecan-3-ol, a Class of Novel 1-Deoxysphingolipid Analogues, during Food Storage</article-title><source>J. Agric. Food Chem.</source><year>2022</year><volume>70</volume><fpage>5151</fpage><lpage>5158</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.1c08065</pub-id><pub-id pub-id-type="pmid">35416040</pub-id></element-citation></ref><ref id="B21-nutrients-17-02881"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>A.H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name></person-group><article-title>The Emerging Mycotoxin 2-Amino-14, 16-Dimethyloctadecan-3-ol (AOD) Alters Transcriptional Regulation and Sphingolipid Metabolism and Undergoes N-Acylation by HepG2 Cells</article-title><source>Toxins</source><year>2025</year><volume>17</volume><elocation-id>413</elocation-id><pub-id pub-id-type="doi">10.3390/toxins17080413</pub-id><pub-id pub-id-type="pmid">40864089</pub-id><pub-id pub-id-type="pmcid">PMC12390525</pub-id></element-citation></ref><ref id="B22-nutrients-17-02881"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>You</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name></person-group><article-title>Loss of the ceramide synthase HYL-2 from Caenorhabditis elegans impairs stress responses and alters sphingolipid composition</article-title><source>J. Biol. Chem.</source><year>2024</year><volume>300</volume><elocation-id>107320</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2024.107320</pub-id><pub-id pub-id-type="pmid">38677510</pub-id><pub-id pub-id-type="pmcid">PMC11145541</pub-id></element-citation></ref><ref id="B23-nutrients-17-02881"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaner</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Allegood</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Sullards</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>A.H.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers</article-title><source>J. Lipid Res.</source><year>2009</year><volume>50</volume><fpage>1692</fpage><lpage>1707</lpage><pub-id pub-id-type="doi">10.1194/jlr.D800051-JLR200</pub-id><pub-id pub-id-type="pmid">19036716</pub-id><pub-id pub-id-type="pmcid">PMC2724058</pub-id></element-citation></ref><ref id="B24-nutrients-17-02881"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Heimberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wilcox</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Desiderio</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dalton</surname><given-names>J.T.</given-names></name></person-group><article-title>Comparative lipoprotein metabolism of myristate, palmitate, and stearate in normolipidemic men</article-title><source>Metabolism</source><year>1996</year><volume>45</volume><fpage>1108</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1016/S0026-0495(96)90010-4</pub-id><pub-id pub-id-type="pmid">8781298</pub-id></element-citation></ref><ref id="B25-nutrients-17-02881"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuzaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimano</surname><given-names>H.</given-names></name></person-group><article-title>Elovl6: A new player in fatty acid metabolism and insulin sensitivity</article-title><source>J. Mol. Med.</source><year>2009</year><volume>87</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1007/s00109-009-0449-0</pub-id><pub-id pub-id-type="pmid">19259639</pub-id></element-citation></ref><ref id="B26-nutrients-17-02881"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lone</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>H&#252;lsmeier</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Saied</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Karsai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arenz</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Eckardstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornemann</surname><given-names>T.</given-names></name></person-group><article-title>Subunit composition of the mammalian serine-palmitoyltransferase defines the spectrum of straight and methyl-branched long-chain bases</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>15591</fpage><lpage>15598</lpage><pub-id pub-id-type="doi">10.1073/pnas.2002391117</pub-id><pub-id pub-id-type="pmid">32576697</pub-id><pub-id pub-id-type="pmcid">PMC7355037</pub-id></element-citation></ref><ref id="B27-nutrients-17-02881"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ohira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Go</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moriya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyaji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakatsuka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nagai</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The Urinary Bladder is Rich in Glycosphingolipids Composed of Phytoceramides</article-title><source>J. Lipid Res.</source><year>2022</year><volume>63</volume><fpage>100303</fpage><pub-id pub-id-type="doi">10.1016/j.jlr.2022.100303</pub-id><pub-id pub-id-type="pmid">36441023</pub-id><pub-id pub-id-type="pmcid">PMC9708920</pub-id></element-citation></ref><ref id="B28-nutrients-17-02881"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gengatharan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Handzlik</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chih</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Ruchhoeft</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Secrest</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordts</surname><given-names>P.</given-names></name><name name-style="western"><surname>Metallo</surname><given-names>C.M.</given-names></name></person-group><article-title>Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans-fat-induced atherosclerosis</article-title><source>Cell Metab.</source><year>2025</year><volume>37</volume><fpage>274</fpage><lpage>290.e279</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2024.10.016</pub-id><pub-id pub-id-type="pmid">39547233</pub-id><pub-id pub-id-type="pmcid">PMC12276992</pub-id></element-citation></ref><ref id="B29-nutrients-17-02881"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>York</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Skadow</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Mowel</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kaffe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.J.</given-names></name><etal/></person-group><article-title>IL-10 constrains sphingolipid metabolism to limit inflammation</article-title><source>Nature</source><year>2024</year><volume>627</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07098-5</pub-id><pub-id pub-id-type="pmid">38383790</pub-id><pub-id pub-id-type="pmcid">PMC10954550</pub-id></element-citation></ref><ref id="B30-nutrients-17-02881"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahawar</surname><given-names>U.</given-names></name><name name-style="western"><surname>Farooq</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vohra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Ceramide sensing by human SPT-ORMDL complex for establishing sphingolipid homeostasis</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>3475</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-39274-y</pub-id><pub-id pub-id-type="pmid">37308477</pub-id><pub-id pub-id-type="pmcid">PMC10261145</pub-id></element-citation></ref><ref id="B31-nutrients-17-02881"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chew</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Torta</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Begum</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sim</surname><given-names>X.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>E.Y.H.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Van Dam</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence</article-title><source>JCI Insight</source><year>2019</year><volume>5</volume><fpage>e126925</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.126925</pub-id><pub-id pub-id-type="pmid">31162145</pub-id><pub-id pub-id-type="pmcid">PMC6629294</pub-id></element-citation></ref><ref id="B32-nutrients-17-02881"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>F.</given-names></name></person-group><article-title>Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>1185</elocation-id><pub-id pub-id-type="doi">10.3390/nu11051185</pub-id><pub-id pub-id-type="pmid">31137828</pub-id><pub-id pub-id-type="pmcid">PMC6566605</pub-id></element-citation></ref><ref id="B33-nutrients-17-02881"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.T.</given-names></name></person-group><article-title>Omega-3 PUFA ameliorates hyperhomocysteinemia-induced hepatic steatosis in mice by inhibiting hepatic ceramide synthesis</article-title><source>Acta Pharmacol. Sin.</source><year>2017</year><volume>38</volume><fpage>1601</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1038/aps.2017.127</pub-id><pub-id pub-id-type="pmid">28933423</pub-id><pub-id pub-id-type="pmcid">PMC5719150</pub-id></element-citation></ref><ref id="B34-nutrients-17-02881"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cinar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Godlewski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jourdan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harvey-White</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kunos</surname><given-names>G.</given-names></name></person-group><article-title>Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing <italic toggle="yes">de novo</italic> synthesis of long-chain ceramides</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1002/hep.26606</pub-id><pub-id pub-id-type="pmid">23832510</pub-id><pub-id pub-id-type="pmcid">PMC3839256</pub-id></element-citation></ref><ref id="B35-nutrients-17-02881"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirkov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver</article-title><source>Metabolism</source><year>2012</year><volume>61</volume><fpage>1523</fpage><lpage>1527</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2012.05.004</pub-id><pub-id pub-id-type="pmid">22738862</pub-id><pub-id pub-id-type="pmcid">PMC3867007</pub-id></element-citation></ref><ref id="B36-nutrients-17-02881"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovilakath</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mauro</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Valentine</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Raucci</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Beutner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>SPTLC3 Is Essential for Complex I Activity and Contributes to Ischemic Cardiomyopathy</article-title><source>Circulation</source><year>2024</year><volume>150</volume><fpage>622</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.123.066879</pub-id><pub-id pub-id-type="pmid">38660786</pub-id><pub-id pub-id-type="pmcid">PMC11333184</pub-id></element-citation></ref><ref id="B37-nutrients-17-02881"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montefusco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jamil</surname><given-names>M.</given-names></name><name name-style="western"><surname>Canals</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saligrama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Allegood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cowart</surname><given-names>L.A.</given-names></name></person-group><article-title>SPTLC3 regulates plasma membrane sphingolipid composition to facilitate hepatic gluconeogenesis</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>115054</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.115054</pub-id><pub-id pub-id-type="pmid">39661520</pub-id><pub-id pub-id-type="pmcid">PMC12004358</pub-id></element-citation></ref><ref id="B38-nutrients-17-02881"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cariello</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Cowart</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>A.J.</given-names></name></person-group><article-title>Sphingosine kinase 1 is required for myristate-induced TNF&#945; expression in intestinal epithelial cells</article-title><source>Prostaglandins Other Lipid Mediat.</source><year>2020</year><volume>149</volume><fpage>106423</fpage><pub-id pub-id-type="doi">10.1016/j.prostaglandins.2020.106423</pub-id><pub-id pub-id-type="pmid">32006664</pub-id><pub-id pub-id-type="pmcid">PMC7292780</pub-id></element-citation></ref><ref id="B39-nutrients-17-02881"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glueck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brunkhorst</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bouzas</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Trautmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pfeilschifter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pfeilschifter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vutukuri</surname><given-names>R.</given-names></name></person-group><article-title>The atypical sphingosine 1-phosphate variant, d16:1 S1P, mediates CTGF induction via S1P2 activation in renal cell carcinoma</article-title><source>FEBS J.</source><year>2022</year><volume>289</volume><fpage>5670</fpage><lpage>5681</lpage><pub-id pub-id-type="doi">10.1111/febs.16446</pub-id><pub-id pub-id-type="pmid">35320610</pub-id></element-citation></ref><ref id="B40-nutrients-17-02881"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glueck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lucaciu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Subburayalu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kestner</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Pfeilschifter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vutukuri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pfeilschifter</surname><given-names>J.</given-names></name></person-group><article-title>Atypical sphingosine-1-phosphate metabolites&#8212;Biological implications of alkyl chain length</article-title><source>Pflugers Arch. Eur. J. Physiol.</source><year>2024</year><volume>476</volume><fpage>1833</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1007/s00424-024-03018-8</pub-id><pub-id pub-id-type="pmid">39297971</pub-id><pub-id pub-id-type="pmcid">PMC11582160</pub-id></element-citation></ref><ref id="B41-nutrients-17-02881"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacicedo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Benjachareowong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruderman</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Ido</surname><given-names>Y.</given-names></name></person-group><article-title>Palmitate-induced apoptosis in cultured bovine retinal pericytes: Roles of NAD(P)H oxidase, oxidant stress, and ceramide</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>1838</fpage><lpage>1845</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.6.1838</pub-id><pub-id pub-id-type="pmid">15919807</pub-id></element-citation></ref><ref id="B42-nutrients-17-02881"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homaidan</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>El-Sabban</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Chakroun</surname><given-names>I.</given-names></name><name name-style="western"><surname>El-Sibai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dbaibo</surname><given-names>G.S.</given-names></name></person-group><article-title>IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells</article-title><source>Mediat. Inflamm.</source><year>2002</year><volume>11</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1080/09629350210313</pub-id><pub-id pub-id-type="pmcid">PMC1781644</pub-id><pub-id pub-id-type="pmid">11926594</pub-id></element-citation></ref><ref id="B43-nutrients-17-02881"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty liver disease</article-title><source>Int. J. Biol. Sci.</source><year>2023</year><volume>19</volume><fpage>311</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.7150/ijbs.78525</pub-id><pub-id pub-id-type="pmid">36594091</pub-id><pub-id pub-id-type="pmcid">PMC9760443</pub-id></element-citation></ref><ref id="B44-nutrients-17-02881"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hose</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naser</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sch&#246;nberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Falkenstein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Papadamakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kleuser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Gulbins</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Cell-intrinsic ceramides determine T cell function during melanoma progression</article-title><source>eLife</source><year>2022</year><volume>11</volume><fpage>e83073</fpage><pub-id pub-id-type="doi">10.7554/eLife.83073</pub-id><pub-id pub-id-type="pmid">36426850</pub-id><pub-id pub-id-type="pmcid">PMC9699697</pub-id></element-citation></ref><ref id="B45-nutrients-17-02881"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Eijk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bijl</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ottenhoff</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Roomen</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Dubbelhuis</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Seeman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ghauharali-van der Vlugt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Overkleeft</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Arbeeny</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Reducing glycosphingolipid content in adipose tissue of obese mice restores insulin sensitivity, adipogenesis and reduces inflammation</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e4723</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0004723</pub-id><pub-id pub-id-type="pmid">19305508</pub-id><pub-id pub-id-type="pmcid">PMC2654925</pub-id></element-citation></ref><ref id="B46-nutrients-17-02881"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bedja</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lad</surname><given-names>V.</given-names></name><name name-style="western"><surname>Iocco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sivakumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bandaru</surname><given-names>V.V.R.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of glycosphingolipid synthesis reverses skin inflammation and hair loss in ApoE-/- mice fed western diet</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>11463</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-28663-9</pub-id><pub-id pub-id-type="pmid">30061606</pub-id><pub-id pub-id-type="pmcid">PMC6065400</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="nutrients-17-02881-f001" orientation="portrait"><label>Figure 1</label><caption><p>Myristic acid (MA) induces reprogramming of canonical d18-sphingolipid metabolism. (<bold>A</bold>) Schematic representation of the involvement of MA in canonical d18-sphingolipid (SL) metabolic pathway. (<bold>B</bold>&#8211;<bold>K</bold>) Quantitative analysis of MA-induced alterations in d18-sphingolipid species (units: pmol/mg protein). (<bold>B</bold>,<bold>C</bold>) Sphingoid base measurements showed reduced d18:0 (<bold>B</bold>) and d18:1 (<bold>C</bold>) levels. (<bold>D</bold>,<bold>E</bold>) Ceramide analysis demonstrated unchanged d18:0-dihydroceramides (DHCer, (<bold>D</bold>)) and increased d18:1-ceramides (Cer, (<bold>E</bold>)). (<bold>F</bold>,<bold>G</bold>) Sphingoid base-1-phosphate (S1P) quantification revealed reduced d18:0-sphinganine-1-phosphate (Sa1P, (<bold>F</bold>)) and d18:1-S1P (<bold>G</bold>). (<bold>H</bold>&#8211;<bold>K</bold>) Glycosphingolipid (GSL) measurements showed decreased d18:0-dihydrohexosylceramides (DHHexCer, sum of dihydro glucosyl- and dihydrogalactosyl-ceramides, (<bold>H</bold>)), and d18:1-lactosylceramides (LacCer, (<bold>K</bold>)), while d18:0-dihydrolactosylceramides (DHLacCer, (<bold>I</bold>)) and d18:1-hexosylceramides (HexCer, sum of glucosyl- and galactosyl-ceramides, (<bold>J</bold>)) showed no significant change. Data are from three independent biological replicates as the black dots indicated. The <italic toggle="yes">p</italic> values are compared with the control group, and analyzed using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test, with * <italic toggle="yes">p</italic> &lt; 0.05, and *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02881-g001.jpg"/></fig><fig position="float" id="nutrients-17-02881-f002" orientation="portrait"><label>Figure 2</label><caption><p>MA modulates sphingolipid-related gene expression profiles. Quantitative PCR analysis of the mRNA expression of serine palmitoyltransferase (SPT) subunit genes (<italic toggle="yes">SPTLC1-3</italic>) (<bold>A</bold>), genes for ceramide synthesis (<italic toggle="yes">DEGS1-2</italic>, <italic toggle="yes">CERS1-6</italic>) (<bold>B</bold>), fatty acid elongase genes (<italic toggle="yes">ELOVL1-7</italic>) (<bold>C</bold>) and S1P synthesis and cleavage genes (<italic toggle="yes">SPHK1-2</italic>, <italic toggle="yes">SGPP1</italic>, <italic toggle="yes">SGPL1</italic>) (<bold>D</bold>). The <italic toggle="yes">p</italic> values are compared to the control group without MA supplementary cells, analyzed using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test from three independent biological experiments (black dots represent individual replicates), with * <italic toggle="yes">p</italic> &lt; 0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02881-g002.jpg"/></fig><fig position="float" id="nutrients-17-02881-f003" orientation="portrait"><label>Figure 3</label><caption><p>MA directs C14:0-CoA incorporation into d18:1-Cer and d18:1-HexCer. (<bold>A</bold>,<bold>B</bold>) Heatmap visualization of log<sub>2</sub>-fold changes in <italic toggle="yes">N</italic>-acyl chain length distribution for (<bold>A</bold>) d18:0-DHCer and (<bold>B</bold>) d18:1-Cer, showed preferential incorporation of C14:0 into d18:1-Cer. (<bold>C</bold>,<bold>D</bold>) Quantitative analysis of the levels of (<bold>C</bold>) d18:0-DHHexCer and (<bold>D</bold>) d18:1-HexCer demonstrated a significant enrichment of <italic toggle="yes">N</italic>-acyl C14:0-containing d18:1-HexCer. (<bold>E</bold>,<bold>F</bold>) Quantification of (<bold>E</bold>) d18:0-DHLacCer and (<bold>F</bold>) d18:1-LacCer revealed divergent regulation between these glycosphingolipids species. Color scale: white represents the mean of all samples, with increasing red intensity indicating higher lipid levels and increasing blue intensity indicating lower levels. For each panel, the maximum positive (red) log<sub>2</sub>FC values and their corresponding fold changes are: 0.4 (~1.3-fold); 0.6 (~1.5-fold); 2.0 (4.0-fold); 0.3 (~1.2-fold). A log<sub>2</sub>FC value of 0 indicates no change from the mean, with positive and negative values representing upward and downward regulation, respectively. The <italic toggle="yes">p</italic> values are compared to the control group without MA supplementary cells, analyzed using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test from three separate biological experiments, with * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02881-g003.jpg"/></fig><fig position="float" id="nutrients-17-02881-f004" orientation="portrait"><label>Figure 4</label><caption><p>MA drives the non-canonical d16-sphingolipid biosynthetic pathway. (<bold>A</bold>) Schematic representation of the d16-sphingolipid synthesis pathway. (<bold>B</bold>,<bold>C</bold>) Quantification of free sphingoid bases showed elevated levels of (<bold>B</bold>) d16:0 and (<bold>C</bold>) d16:1 (units: pmol/mg protein). (<bold>D</bold>,<bold>E</bold>) Ceramide analysis revealed increased (<bold>D</bold>) d16:0-DHCer and (<bold>E</bold>) d16:1-Cer levels (units: pmol/mg protein). (<bold>F</bold>,<bold>G</bold>) S1P quantification demonstrated (<bold>F</bold>) non-affected d16:0-Sa1P and (<bold>G</bold>) enhanced d16:1-S1P production (units: pmol/mg protein). (<bold>H</bold>&#8211;<bold>K</bold>) GSL measurements revealed increases in d16:0-DHHexCer (<bold>H</bold>) and d16:0-DHLacCer (<bold>I</bold>), while d16:1-HexCer (<bold>J</bold>) and d16:1-LacCer (<bold>K</bold>) were also significantly elevated (units: pmol/mg protein). (<bold>L</bold>&#8211;<bold>O</bold>) Heatmap analyses of <italic toggle="yes">N</italic>-acyl chain length distributions (C14~C24) for (<bold>L</bold>) d16:0-DHCer, (<bold>M</bold>) d16:1-Cer, (<bold>N</bold>) d16:1-HexCer, and (<bold>O</bold>) d16:1-LacCer, with log<sub>2</sub>-fold changes indicating MA-induced remodeling. Color scale: white color denotes the mean value across all samples, where progressive reddening reflects higher lipid levels and progressive bluing reflects lower levels. For each panel, the maximum positive (red) log<sub>2</sub>FC values and their corresponding fold changes are: 1.0 (2.0-fold), 0.5 (~1.4-fold). A log<sub>2</sub>FC value of 0 indicates no change from the mean, with positive and negative values representing upward and downward regulation, respectively. The <italic toggle="yes">p</italic> values are compared to the control group without MA supplementary cells, analyzed using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test from three separate biological experiments, with * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01; and *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02881-g004.jpg"/></fig><fig position="float" id="nutrients-17-02881-f005" orientation="portrait"><label>Figure 5</label><caption><p>MA induces sphingolipid metabolic remodeling via mRNA-level upregulation of <italic toggle="yes">SMPD2</italic> and <italic toggle="yes">SMPD3</italic>, potentially driving sphingomyelin (SM) degradation and ceramide elevation. (<bold>A</bold>&#8211;<bold>G</bold>) Quantitative analysis of total lipid contents for d18- and d16-series sphingolipids (units: pmol/mg protein): d18- and d16- total (<bold>A</bold>) DHCer, (<bold>B</bold>) Cer, (<bold>C</bold>) DHHexCer, (<bold>D</bold>) HexCer, (<bold>E</bold>) DHLacCer, (<bold>F</bold>) LacCer, and (<bold>G</bold>) total SM. (<bold>H</bold>) The mRNA expression of genes involved in ceramide transfer protein (CERT) and SM metabolism (SGMS1-2, SMPD1-3) in HepG2 cells after 24 h MA treatment. (<bold>I</bold>) Heatmap showed log<sub>2</sub>-fold changes in SM acyl chain length distribution (d30~d44; e.g., d30 likely denotes a d16-sphingoid base with a C14 <italic toggle="yes">N</italic>-acyl chain) in MA-treated HepG2 cells. Color scale: white denotes the sample mean, with intensifying red indicating elevated lipid levels and deepening blue signifying reduced levels. The scale is calibrated such that the maximum positive (red) log<sub>2</sub>FC values correspond to 1.0 (2.0-fold increase), and 0.5 (~1.4-fold increase), respectively. A log<sub>2</sub>FC value of 0 indicates no change from the mean, with positive and negative values representing upward and downward regulation, respectively. The <italic toggle="yes">p</italic> values are compared to the control group without MA supplementary cells, analyzed using a two-tailed Student&#8217;s <italic toggle="yes">t</italic>-test from three separate biological experiments (black dots represent individual replicates), with * <italic toggle="yes">p</italic> &lt; 0.05; ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nutrients-17-02881-g005.jpg"/></fig></floats-group></article></pmc-articleset>